Equity Overview
Price & Market Data
Price: $0.65
Daily Change: -$0.0311 / 4.78%
Daily Range: $0.638 - $0.718
Market Cap: $34,125,213
Daily Volume: 1,448,365
Performance Metrics
1 Week: -6.49%
1 Month: -1.52%
3 Months: -12.28%
6 Months: -5.80%
1 Year: -36.89%
YTD: -33.54%
Company Details
Employees: 64
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.